Abstract:Background: CD8+ T cells are a highly diverse population of cells with distinct phenotypic functions that can influence immunotherapy outcomes. Further insights on the roles of CD8+ specificities and TCR avidity of naturally arising tumor-specific T cells, where both high and low avidity T cells recognizing the same peptide-major histocompatibility complex (pMHC) coexist in the same tumor, are crucial for understanding T cell exhaustion and resistance to PD-1 immunotherapy. Methods: CT26 models were treated with anti-PD-1 on days 3, 6 and 9 following subcutaneous tumor implantation generating variable responses during early tumor development. Tetramer staining was performed to determine the frequency and avidity of CD8+ T cells targeting the tumor-specific epitope GSW11 and confirmed with tetramer competition assays. Functional characterization of high and low avidity GSW11-specific CD8+ T cells was conducted using flow cytometry and bulk RNA-seq. In vitro cytotoxicity assays and in vivo adoptive transfer experiments were performed to determine the cytotoxicity of high and low avidity populations. Results: Treatment success with anti-PD-1 was associated with the preferential expansion of low avidity (Tetlo) GSW11-specific CD8+ T cells with Vβ TCR expressing clonotypes. High avidity T cells (Tethi), if present, were only found in progressing PD-1 refractory tumors. Tetlo demonstrated precursor exhausted or progenitor T cell phenotypes marked by higher expression of Tcf-1 and T-bet, and lower expression of the exhaustion markers CD39, PD-1 and Eomes compared with Tethi, whereas Tethi cells were terminally exhausted. Transcriptomics analyses showed pathways related to TCR signaling, cytotoxicity and oxidative phosphorylation were significantly enriched in Tetlo found in both regressing and progressing tumors compared with Tethi, whereas genes related to DNA damage, apoptosis and autophagy were downregulated. In vitro studies showed that Tetlo exhibits higher cytotoxicity than Tethi. Adoptive transfer of Tetlo showed more effective tumor control than Tethi, and curative responses were achieved when Tetlo was combined with two doses of anti-PD-1. Conclusions: Targeting subdominant T cell responses with lower avidity against pMHC affinity neoepitopes showed potential for improving PD-1 immunotherapy. Future interventions may consider expanding low avidity populations via vaccination or adoptive transfer.

A GAPDH serotonylation system couples CD8 + T cell glycolytic metabolism to antitumor immunity

Targeting Glycosylated PD-1 Induces Potent Antitumor Immunity

Metabolic reprogramming of antitumor CD8+ T cells by modulation of GSH-Gpx4 axis

Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy.

Activation and antitumor immunity of CD8 + T cells are supported by the glucose transporter GLUT10 and disrupted by lactic acid

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

pH-Controlled chemoselective rapid azo-coupling reaction (CRACR) enables global profiling of serotonylation proteome in cancer cells

Siglec‐G Suppresses CD8+ T Cells Responses through Metabolic Rewiring and Can be Targeted to Enhance Tumor Immunotherapy

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity

Tumor Aerobic Glycolysis Confers Immune Evasion Through Modulating Sensitivity to T Cell-Mediated Bystander Killing Via TNF-α.

TET2 Promotes Anti-Tumor Immunity by Governing G-MDSCs Andcd8+t-Cell Numbers

The physiology, pathology and potential therapeutic application of serotonylation

Enhanced Interferon-Gamma Secretion and Antitumor Activity of T-Lymphocytes Activated by Dendritic Cells Loaded with Glycoengineered Myeloma Antigens

Modulation Of Cd8(+) Memory Stem T Cell Activity And Glycogen Synthase Kinase 3 Beta Inhibition Enhances Anti-Tumoral Immunity In Gastric Cancer

Microbial short-chain fatty acids modulate CD8+ T cell responses and improve adoptive immunotherapy for cancer

Transgelin 2 guards T cell lipid metabolic programming and anti-tumor function

H 2 S-Prdx4 axis mitigates Golgi stress to bolster tumor-reactive T cell immunotherapeutic response

Promoting anti-tumor immunity by targeting TMUB1 to modulate PD-L1 polyubiquitination and glycosylation

TET 2 promotes anti‐tumor immunity by governing G‐ MDSC s and CD 8 + T‐cell numbers

Genetically engineering glycolysis in T cells increases their antitumor function

Fueling T-cell Antitumor Immunity: Amino Acid Metabolism Revisited